Michael Ullmann, Executive Vice President and General Counsel of Johnson & Johnson, Retires; Elizabeth Forminard appointed General Counsel, effective October 17, 2022

NEW BRUNSWICK, NJ–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) today announced that Michael (Mike) Ullmann will step down as Executive Vice President, General Counsel at the end of this year, after 33 years of leadership and service to of the society. Throughout his distinguished career, Mr. Ullmann has worked with the organization’s Board of Directors and partnered with four corporate CEOs to shape and build Johnson & Johnson into the most broadly based healthcare company established in the world.

He will be succeeded in this role by Elizabeth (Liz) Forminard, a strong Credo-based leader who has had an exceptional career with depth and breadth in the company‘s pharmaceutical, MedTech and consumer health sectors. Ms. Forminard will also be appointed as a member of Johnson & Johnson’s Executive Committee, effective October 17, 2022. Mr. Ullmann and Ms. Forminard will work together during a transition period until Mr. Ullmann’s retirement at the end of this term. year.

“For three decades, Mike has set the standard for Credo leadership within the company. I thank him for his unwavering commitment to helping achieve our goal of advancing health for humanity,” said Joaquin Duato, President and CEO of Johnson & Johnson “Throughout his tenure, Mike has guided the company through a changing global environment with respect and clarity, always keeping our patients and customers at the center of all decisions.”

Mr. Ullmann joined Johnson & Johnson as a mergers and acquisitions lawyer in 1989 and has since held positions of increasing responsibility within the company’s legal department, eventually serving as Chief Legal Officer over the past 11 last years. During this time, Mr. Ullmann led the company through complex issues while ensuring that all company standards and policies reflected the needs of a changing world and a new generation of people. employees, underscoring a commitment to diversity, equity and inclusion (DEI) and reinforcing the company’s dedication to the health of humanity. A dedicated advocate for DEI, he has also served as the executive sponsor of the company’s Hispanic and Latino Employee Resource Group and as a member of the Leadership Council on Legal Diversity, an organization that works to build a more legal profession. open and diverse.

Liz Forminard has been with Johnson & Johnson for 16 years, having served as general counsel in each of the pharmaceutical, consumer healthcare and medical technology sectors, as well as global vice president leading the corporate governance and many other functional and business roles. during this time. Throughout her tenure on the Legal Department Executive Committee (LDEC), Ms. Forminard has built and led global teams that share her passion for the role the law can play in driving innovation and influencing of the external environment to enable positive patient outcomes. In her most recent role, Ms. Forminard served as General Counsel for the Pharmaceutical Legal Group and a member of the Pharmaceutical Group’s Operating Committee, leading the global legal function for the industry and for Johnson & Johnson Global External Innovation and Global Public Health, where she led programs to ensure optimal and aligned intellectual property, regulatory and business strategies internally, and helped shape the global healthcare environment externally.

“I am delighted to appoint Liz to this important position and will draw on her business acumen and understanding of patient and customer needs during this pivotal time for our company,” said Mr. Duato. “I am confident that his distinguished experience and leadership will help us find new avenues to bring innovative healthcare solutions to those in need around the world.”

About Johnson & Johnson

At Johnson & Johnson, we believe that good health is the foundation for vibrant lives, thriving communities and progress. That’s why, for more than 130 years, we’ve focused on the well-being of people at all ages and at every stage of life. Today, as the largest and most widely-located healthcare company in the world, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and make healthy minds, bodies and environments accessible to everyone, everywhere. We unite our hearts, our science and our ingenuity to profoundly change the trajectory of human health.

Cautions Regarding Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to rely on any such forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could differ materially from Johnson & Johnson’s expectations and projections. A list and descriptions of the risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned Caution Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s subsequent quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these documents are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statements made in this release speak only as of the date of this release. Johnson & Johnson does not undertake to update forward-looking statements as a result of new information or future events or developments.

About the author